
According to Benzinga Pro data, during Q4, RAPT Therapeutics (NASDAQ:RAPT) posted sales of $756.00 thousand. Earnings were up 3.87%, but RAPT Therapeutics still reported an overall loss of $17.93 million. In Q3, RAPT Therapeutics brought in $966.00 thousand in sales but lost $18.65 million in earnings.